Oncology partners, Parkinson’s partners, expanded European Commission, expanded FDA, and bacterial vaccines

Devices with tech enablement, nano particles, Chinese approvals, and a massive series B for biotechnology

We’ve got a new name, gene therapy buyout, a lion of an approval, and an inescapable spotlight.

Acquiring the acquired, EHR acquisition, first approvals, and a new fund for the new year

Antitrust AI, development AI, expanded approval, mega seeds, and biosimilar SPACs

Double acquisitions in Switzerland, FDA holds and what that means, CMV therapy, rare + oncology continues, BioCryst draws millions, and deer

Top dollar lab notes, lab consolidation, RNA sells, and two new approval areas

A giant breaks in two, acquisitions in Women’s Health, Medicare cost, rare approvals, more CRISPR, and a legacy

Roche and Novartis part ways, Alphabet likes AI, Pfizer 89%, Series A, B, and the money that gets you there

This week, we have a special bonus interview with Danielle Coe, founder of Black Women in Clinical Research.

Unique therapies including anti-opioid overdose, ocular implants, fish skin, UV light, digital therapeutics, and the impact of approvals

The 26-year pipeline, CMDO divestment, oncology, and movement among COVID19 Therapies

Less than spiffy SPACs, big brains big money, Malaria buzz, vaccines, tests, series A, and Voyager gets a renewed lease on life

$11.5B acquisitions, we play “Who’s on First”, COVID19 therapy news, cancer Vaccines may be on the way, and CAR T for cancer is here to stay

Double approval, double acquisition, $200M for tests, $200M for prostate robots, $450M for $1B worth of gummies

BeiGene’s oncology machine, China oncology pipelines, COVID costs, two new FDA approvals, $5B life science merger, and Hong Kong joins US SPAC party

$1.5B deal, $1.9B merger, protein degraders get backing, an old bird has new tricks, and another billion-dollar valuation for CRISPR

This week, I go on vacation and give you a special bonus interview with Sam Searcy, founder and CEO of CliniStart and former NC State Senator

The Cassava saga, Reify goes big… too big? Humacyte SPAC, vax news you already know, and a new growth hormone therapy – approved!

Alphabet buys, uncertain futures, new biotech funds, HIF-2a, PD-1, and a China Biotech emerges.